Graphene Manufacturing Group Ltd. secured approximately US$10 million through a private placement by issuing 6.47 million shares at CA$2.15 each, pending TSX Venture Exchange approval. The funds will be used to scale up graphene and battery cell production, commercialize liquid graphene products, and support general corporate needs. This investment validates GMG's technology and supports its growth strategy, especially in North America. The company aims to advance its graphene-enhanced energy-saving products and next-generation battery development.
Graphene Manufacturing Group Ltd. raised about US$10 million through a private placement. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Sep 22, 2026 17:41 WIB: out of 34 priced US stocks, 14 rose and 19 fell. Notable movers include PPG Industries at USD 104.02 with a 1-day change of -0.87% and Pluang order activity of 14% Sell / 86% Buy, Gold Fields Limited at USD 42.34 with a 1-day change of +0.83% and Pluang order activity of 6% Sell / 94% Buy, and BHP Billiton Limited at USD 86.74 with a 1-day change of +0.76% and Pluang order activity of 89% Sell / 11% Buy.
Qualcomm will pay a dividend of $0.92 per share on September 24 to shareholders who owned the stock before September 3. This payout rewards investors with a significant return, though owning enough shares for a large payment requires substantial inve...
VICI Properties Inc. is expected to face increased refinancing costs as its upcoming debt maturities may be repriced significantly above current fixed rates. The company's rent escalators, mostly capped, may not keep pace with inflation if it stays a...
Binance purchased $100 million worth of Circle shares, acquiring 1.24 million shares at $80.84 each through a private placement that closed on September 17. Under a new five-year partnership, Circle will pay Binance monthly fees based on USDC stablec...
Tempus AI reported a 22% revenue increase in Q2 2026, improved profit margins, and raised its full-year guidance despite ongoing operating losses. The company’s acquisition of Personalis addresses a crucial gap in minimal residual disease (MRD) monit...
Viking Therapeutics reported that VK2735, a dual GLP-1/GIP receptor agonist, achieved up to 22% placebo-adjusted weight loss by week 33 in a study with no weight loss plateau observed. The drug maintained up to 97% of weight loss with every-other-wee...
